ghmds | 20783
MDS Panel Mutations
Keywords:
ASXL1
BCOR
BRAF
CALR
CBL
CEBPA
CSF3R
DNMT3A
ETV6
EZH2
GATA2
IDH1
IDH2
JAK2
KIT
KRAS
MDS
MDS
MPL
Myelodysplastic syndrome NGS
NF1
NPM1
NRAS
PTPN11
RUNX1
SETBP1
SF3B1
SF3B1 mutation
SRSF2
STAG2
TET2
TP53
U2AF1
WT1
ZRSR2 Myelodysplastic neoplasms
Status
Hint |
ASXL1, BCOR, BRAF, CALR, CBL, CEBPA, CSF3R, DNMT3A, ETV6, EZH2, GATA2, IDH1, IDH2, JAK2, KIT, KRAS, MPL, NF1, NPM1, NRAS, PTPN11, RUNX1, SETBP1, SF3B1, SRSF2, STAG2, TET2, TP53, U2AF1, WT1, ZRSR2 | There is a possibility of excess information occurring with this analysis. This will be communicated, unless it is noted otherwise when placing the order. | Since in rare cases there may also be indications of hereditary changes, the GUMG (Federal Law on Genetic Testing in Humans) provides for the patient to be informed accordingly (see www.viollier.ch/en/SGMG_consent).
|
---|---|
Min. volume | 4 mL |
Stability |
Stability
2 days / 18-25°C
|
Duration | 1 week |
Frequency | 1 x per week |
Method | Next Generation Sequencing |
Price/Rate
Price |
Price
CHF 2’554.90
|
---|---|
Rate |
Rate
2'554.90 TP
|